Soligenix, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNGX research report →
Companywww.soligenix.com
Soligenix, Inc. , a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions.
- CEO
- Christopher J. Schaber
- IPO
- 1994
- Employees
- 14
- HQ
- Princeton, NJ, US
Price Chart
Valuation
- Market Cap
- $4.00M
- P/E
- -0.36
- P/S
- 0.00
- P/B
- 1.28
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -246.04%
- ROIC
- -327.03%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-11,080,380 · -34.04%
- EPS
- $-2.14 · 57.03%
- Op Income
- $-11,845,476
- FCF YoY
- -22.17%
Performance & Tape
- 52W High
- $6.23
- 52W Low
- $0.28
- 50D MA
- $0.94
- 200D MA
- $1.56
- Beta
- 1.31
- Avg Volume
- 811.19K
Get TickerSpark's AI analysis on SNGX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 11, 25 | Straube Richard | other | 10,000 |
| Dec 11, 25 | Donini Oreola | other | 100,000 |
| Dec 11, 25 | Guarino Jonathan L. | other | 100,000 |
| Dec 11, 25 | SCHABER CHRISTOPHER J | other | 200,000 |
| Oct 2, 25 | SCHABER CHRISTOPHER J | buy | 15,132 |
| Jun 20, 25 | LAPOINTE ANTHONY GREGG | other | 17,647 |
| Jun 20, 25 | ZELDIS JEROME B | other | 17,647 |
| Jun 20, 25 | RUBIN ROBERT J. | other | 17,647 |
| Jun 20, 25 | Parks Diane L. | other | 17,647 |
| Dec 12, 24 | Parks Diane L. | other | 8,646 |
Our SNGX Coverage
We haven't published any research on SNGX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SNGX Report →